Resumen
The physiological role of leptin is thought to be a driving force to reduce food intake and increase energy expenditure. However, leptin therapies in the clinic have failed to effectively treat obesity, predominantly due to a phenomenon referred to as leptin resistance. The mechanisms linking obesity and the associated leptin resistance remain largely unclear. With various mouse models and a leptin neutralizing antibody, we demonstrated that hyperleptinemia is a driving force for metabolic disorders. A partial reduction of plasma leptin levels in the context of obesity restores hypothalamic leptin sensitivity and effectively reduces weight gain and enhances insulin sensitivity. These results highlight that a partial reduction in plasma leptin levels leads to improved leptin sensitivity, while pointing to a new avenue for therapeutic interventions in the treatment of obesity and its associated comorbidities.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 706-719.e6 |
| Publicación | Cell Metabolism |
| Volumen | 30 |
| N.º | 4 |
| DOI | |
| Estado | Published - oct 1 2019 |
Nota bibliográfica
Copyright © 2019 Elsevier Inc. All rights reserved.ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
-
Good health and well being
Huella
Profundice en los temas de investigación de 'Partial Leptin Reduction as an Insulin Sensitization and Weight Loss Strategy'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver